Form 4: Nuvation Bio CCO Reports Significant Stock Option Grant

Nuvation Bio's Chief Commercial Officer, Colleen Sjogren, reported the grant of 748,130 stock options and beneficial ownership of 84,000 Class A Common Stock.

Summary

• Colleen Sjogren, Chief Commercial Officer of Nuvation Bio Inc. (NUVB), reported changes in her beneficial ownership.
• She beneficially owns 84,000 shares of Class A Common Stock directly, which includes 3,000 shares acquired on November 19, 2025, under the 2021 Employee Stock Purchase Plan.
• Sjogren was granted 748,130 stock options with an exercise price of $5.91 per share on February 27, 2026.
• These options will vest as to 25% on the one-year anniversary of February 27, 2026, and monthly thereafter over the subsequent 36 months, contingent on her continuous service.
• The stock options have an expiration date of February 26, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the grant of stock options to the Chief Commercial Officer aligns her incentives with long-term shareholder value creation, demonstrating continued commitment to the company.

Positives

• The grant of 748,130 stock options to the Chief Commercial Officer aligns management's long-term incentives with shareholder value.
• The beneficial ownership of 84,000 Class A Common Stock, including shares from an employee stock purchase plan, indicates a personal investment in the company's success.

Future Outlook

The stock options granted to the Chief Commercial Officer will vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date (February 27, 2027) and the remainder vesting monthly over the subsequent 36 months, subject to continuous employment.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like the Chief Commercial Officer is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to incentivize long-term performance and align executive interests with those of shareholders, particularly given the extended development cycles and regulatory hurdles inherent in the sector.

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Commercial Officer's financial interests with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: The mention of the 2021 Employee Stock Purchase Plan indicates broader employee participation in equity ownership.

Next Steps

• The stock options will begin vesting on February 27, 2027, with subsequent monthly vesting over the following 36 months.

Key Dates

Keywords

Nuvation Bio, NUVB, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Colleen Sjogren, Chief Commercial Officer, Equity Compensation